Advertisement
UK markets close in 3 hours 35 minutes
  • FTSE 100

    8,090.61
    +50.23 (+0.62%)
     
  • FTSE 250

    19,712.48
    -6.89 (-0.03%)
     
  • AIM

    755.17
    +0.48 (+0.06%)
     
  • GBP/EUR

    1.1670
    +0.0026 (+0.22%)
     
  • GBP/USD

    1.2512
    +0.0050 (+0.40%)
     
  • Bitcoin GBP

    51,018.55
    -2,121.85 (-3.99%)
     
  • CMC Crypto 200

    1,356.29
    -26.29 (-1.90%)
     
  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     
  • DOW

    38,460.92
    -42.77 (-0.11%)
     
  • CRUDE OIL

    82.97
    +0.16 (+0.19%)
     
  • GOLD FUTURES

    2,342.70
    +4.30 (+0.18%)
     
  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     
  • HANG SENG

    17,284.54
    +83.27 (+0.48%)
     
  • DAX

    17,955.82
    -132.88 (-0.73%)
     
  • CAC 40

    8,009.77
    -82.09 (-1.01%)
     

Novartis Expects FDA and EMA Approvals for Aimovig in 2018

Novartis Expects FDA and EMA Approvals for Aimovig in 2018

Novartis: What Are the Major Growth Drivers for 2018? Aimovig, which is Novartis’s (NVS) investigational migraine prophylaxis therapy, is currently under review by the FDA and the European Medicines Agency (or EMA). More than 10.0% of the adults in the world suffer from migraine.